Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) induce cell death by exploiting the absence of homologous recombination in cancer cells harboring mutations in the BRCA1/BRCA2 genes (1). This evidence concerns the gene PARP1 and cancer.